The Kansas City Clinical Oncology Program (KCCOP), originally funded by the National Cancer Institute in 1983, and continued in 1987, 1990, 1995, and 1999, is a community-wide cooperative program of 11 community hospitals, the Kansas City Cancer Center, and the majority of Kansas City's oncologists. The KCCOP is a 501(c)(3) not-for-profit organization whose mission is to support and coordinate community participation in NCI sponsored cancer clinical trials developed by the NCI Cooperative Group Research Bases. The Administrative Office of the KCCOP oversees the administrative and regulatory responsibilities of the program, including the submission of quarterly Progress Reports to NCI, submission of research studies for IRB review, and data and investigational drug management. In addition, the Administrative Office ensures the training of investigators and staff in human research participants'protections and oversees the quality assurance program for the KCCOP. The KCCOP Board of Directors is composed of administrators from the components of the program, and provides governance and fiscal oversight. The Board also oversees the KCCOP Institutional Review Board, which reviews all Cooperative Group research trials for the KCCOP components. During the next grant period the KCCOP projects an annual accrual of 160-170 credits on treatment protocols and 120 on cancer control protocols using seven research bases: SWOG, M.D. Anderson Cancer Center, NSABP, RTOG, GOG, CALGB, and the University of Rochester Cancer Center (URCC) as well as the Clinical Trials Support Unit (CTSU) mechanism. The KCCOP has strong support from its 12 members that further enhances its ability to reach underserved and minority groups within the catchment area.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA035176-26S1
Application #
8134730
Study Section
Special Emphasis Panel (ZCA1-SRRB-D (J1))
Program Officer
Whitman, Cynthia B
Project Start
1983-09-15
Project End
2011-05-31
Budget Start
2009-06-01
Budget End
2011-05-31
Support Year
26
Fiscal Year
2010
Total Cost
$510,000
Indirect Cost
Name
Kansas City Clinical Oncology Program
Department
Type
DUNS #
148680262
City
Prairie Village
State
KS
Country
United States
Zip Code
66208
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Ji, Yongli; Rankin, Cathryn; Grunberg, Steven et al. (2015) Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005. J Clin Oncol 33:4093-8
Lee, Sylvia M; Moon, James; Redman, Bruce G et al. (2015) Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer 121:432-440
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Othus, Megan; Appelbaum, Frederick R; Petersdorf, Stephen H et al. (2015) Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 21:559-64
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Philip, Philip A; Goldman, Bryan; Ramanathan, Ramesh K et al. (2014) Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWO Cancer 120:2980-5
Goldkorn, Amir; Ely, Benjamin; Quinn, David I et al. (2014) Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol 32:1136-42
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7

Showing the most recent 10 out of 147 publications